Back to Journals » Clinical Ophthalmology » Volume 7

Lymphocyte infiltration in CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy

Authors Mahajan VB, Lin JH

Received 9 April 2013

Accepted for publication 1 May 2013

Published 3 July 2013 Volume 2013:7 Pages 1339—1345


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Vinit B Mahajan,1,2 Jonathan H Lin3

1Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA; 2Omics Laboratory, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; 3Departments of Pathology and Ophthalmology, University of California San Diego, La Jolla, CA, USA

Purpose: To describe immunohistopathological findings in autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV).
Methods: An enucleated eye specimen from a patient with Stage V ADNIV was examined using standard histopathological methods and lymphocyte markers.
Results: A c.731T>C CAPN5 mutation resulted in a p.Leu244Pro substitution in calpain-5. The eye showed exudative retinal detachment and neovascularization, intraocular fibrosis, and features of phthisis bulbi. Chronic inflammatory CD3-positive cell infiltrates were identified throughout the uvea, vitreous and retina, consistent with chronic uveitis.
Conclusion: Mutations in CAPN5 trigger autoimmune uveitis characterized by inflammatory T-cells and severe neovascularization.

Keywords: autosomal dominant neovascular inflammatory vitreoretinopathy, ADNIV, CAPN5, uveitis, CD3

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]